Strengthening Competitiveness in the Clinical Testing Business

「In the clinical testing business, we sought to strengthen new customer acquisition and expand business performance by optimizing selling prices and conducting in-depth sales activities such as expanding sales of new and priority testing items to existing users. As a result, revenue from the clinical testing business increased 5.1% from the previous fiscal year.」

「In the clinical testing business, we sought to strengthen new customer acquisition and expand business performance by optimizing selling prices and conducting in-depth sales activities such as expanding sales of new and priority testing items to existing users. As a result, revenue from the clinical testing business increased 5.1% from the previous fiscal year.」

「In the clinical testing business, we sought to strengthen new customer acquisition and expand business performance by optimizing selling prices and conducting in-depth sales activities such as expanding sales of new and priority testing items to existing users. As a result, revenue from the clinical testing business increased 6.1% year on year.」

「In the clinical testing business, we sought to strengthen new customer acquisition and expand business performance through in-depth sales activities such as expanding sales of new and priority testing items to existing users, as well as optimizing selling prices. As a result, revenue from the clinical testing business increased 3.5% from the previous fiscal year.」

「In the clinical testing business, we sought to strengthen new customer acquisition and expanded sales of new, proprietary and priority testing items to existing users through in-depth sales activities to expand business performance. As a result, revenue from the clinical testing business increased 2.0% year on year.」

「In the clinical testing business, we sought to expand business performance by pursuing new customer acquisition and conducting in-depth sales activities for existing users, including expanding sales of new, proprietary and priority testing items. However, revenue from the clinical testing business decreased 14.4% from the previous fiscal year because of the substantial impact of the decline in the number of tests related to the novel coronavirus.」

「In the clinical testing business, we sought to expand business performance by pursuing new customer acquisition and conducting in-depth sales activities for existing users, including expanding sales of new, proprietary and priority testing items. However, revenue from the clinical testing business decreased 16.3% year on year because of the substantial impact of the decline in the number of COVID-19 tests.」

「In the clinical testing business, we sought to expand business performance by pursuing new customer acquisition and conducting in-depth sales activities for existing users, including expanding sales of new, proprietary and priority testing items. However, revenue from the clinical testing business decreased 17.7% year on year because of the substantial impact of the decline in the number of tests related to the novel coronavirus.」

「In the clinical testing business, we sought to expand business performance by pursuing new customer acquisition and conducting in-depth sales activities for existing users, including expanding sales of new, proprietary and priority testing items. However, revenue from the clinical testing business decreased 14.3% year on year because of the substantial impact of the decline in the number of tests related to the novel coronavirus.」

「In the clinical testing business, we sought to expand business performance by pursuing new customer acquisition and conducting in-depth sales activities for existing users, including expanding sales of new, proprietary and priority testing items. However, revenue from the clinical testing business decreased 10.3% year on year because of the substantial impact of lower reimbursement rates for testing related to the novel coronavirus.」

「In the clinical testing business, we sought to expand business performance by pursuing new customer acquisition and conducting in-depth sales activities for existing users, including expanding sales of new, proprietary and priority testing items. However, revenue from the clinical testing business decreased 13.7% year on year because of the substantial impact of lower reimbursement rates for testing related to the novel coronavirus.」

「In the clinical testing business, we pursued new customer acquisition and conducted in-depth sales activities such as expanding sales of new, proprietary and priority testing items to expand business performance. However, revenue from the clinical testing business decreased 15.3% year on year because of the substantial impact of lower reimbursement rates for testing related to the novel coronavirus.」

「Orders for PCR testing increased as the number of new infections rose. We have also begun accepting contracts for screening tests to identify variants and for genome analysis.」

「In the clinical testing business, we pursued new customer acquisition and conducted in-depth sales activities such as expanding sales of new, proprietary and priority testing items to expand business performance. Revenue from the clinical testing business increased 41.5% year on year as testing related to the novel coronavirus remained firm. Although waves of expansion and containment of infections are expected in the future, we will continue to develop our testing structure so that we can respond to changing circumstances.」

「In the clinical testing business, we pursued new customer acquisition and conducted in-depth sales activities such as expanding sales of new, proprietary and priority testing items to expand business performance. Revenue from the clinical testing business increased 64.2% year on year as testing related to the novel coronavirus remained firm. We have also newly begun accepting PCR pooling tests and genome analysis contracts. We will continue to develop our testing structure so that we can respond to changing circumstances.」

「In the clinical testing business, we pursued new customer acquisition and conducted in-depth sales activities such as expanding sales of new, proprietary and priority testing items to expand business performance. Revenue from the clinical testing business increased 86.0% year on year as testing related to the novel coronavirus remained firm. We will continue to develop our testing structure, including genome analysis, so that we can respond to changing circumstances.」

「In the clinical testing business, we continued to pursue new customer acquisition and conducted in-depth sales activities such as expanding sales of new, proprietary and priority testing items to expand business performance. For novel coronavirus (SARS-CoV-2) testing, as announced on 15 December 2020, we have been expanding testing capacity and strengthening our structure so that our 10 laboratories nationwide can process 20,900 tests per day in response to the rapid increase in testing demand. The actual number of contracted tests also increased substantially as a result. Revenue from the clinical testing business increased 7.2% year on year.」

「In the clinical testing business, we sought to strengthen new customer acquisition and conducted in-depth sales activities such as expanding sales of new, proprietary and priority testing items to expand business performance. In addition, for novel coronavirus (SARS-CoV-2) testing, we have been expanding capacity and strengthening our testing structure so that we can provide more tests. Although the number of tests had begun to recover from June, following the lifting of the state of emergency declaration related to the spread of the novel coronavirus, the number of tests decreased during the cumulative consolidated second quarter. Accordingly, revenue from the clinical testing business decreased 2.6% year on year.」

「In the clinical testing business, we sought to strengthen new customer acquisition and conducted in-depth sales activities such as expanding sales of new, proprietary and priority testing items to expand business performance. In addition, for novel coronavirus (SARS-CoV-2) testing, we have been expanding capacity and strengthening our testing structure so that we can provide more tests. However, the number of tests fell 19.5% due to patients refraining from seeking medical care amid the spread of the novel coronavirus. Accordingly, revenue from the clinical testing business decreased 15.2% year on year.」

「In the clinical testing business, we sought to strengthen new customer acquisition and conducted in-depth sales activities such as expanding sales of new, proprietary and priority testing items to expand business performance. In addition, as part of our group strategy, we acquired shares in ㈱東海細胞研究所 and made the company a consolidated subsidiary from the current fiscal year. As a result, revenue from the clinical testing business increased 4.5% year on year.」

「In the clinical testing business, we sought to strengthen new customer acquisition and conducted in-depth sales activities such as expanding sales of new, proprietary and priority testing items to expand business performance. In addition, as part of our group strategy, we acquired shares in ㈱東海細胞研究所 and made the company a consolidated subsidiary from the current fiscal year. As a result, revenue from the clinical testing business increased 5.5% year on year.」

「In the clinical testing business, we sought to strengthen new customer acquisition and conducted in-depth sales activities such as expanding sales of new, proprietary and priority testing items to expand business performance. In addition, as part of our group strategy, we acquired shares in ㈱東海細胞研究所 and made the company a consolidated subsidiary from the current fiscal year. As a result, revenue from the clinical testing business increased 3.4% year on year.」

「Regarding our contracted testing structure, at BML総合研究所, our main laboratory, we will develop new testing methods using next-generation sequencers and mass spectrometers, and study further automation in areas such as bacteriological testing.」

「In the clinical testing business, although we were affected by natural disasters and the low number of operating days, we sought to strengthen new customer acquisition and conducted in-depth sales activities such as expanding sales of priority testing items to existing users to expand business performance. As a result, revenue from the clinical testing business increased 2.6% year on year.」

「In the clinical testing business, we sought to strengthen new customer acquisition and conducted in-depth sales activities such as expanding sales of priority testing items to existing users to expand business performance. As a result, revenue from the clinical testing business increased 1.3% year on year.」

「In the clinical testing business, we sought to strengthen new customer acquisition and conducted in-depth sales activities such as expanding sales of priority testing items to existing users to expand business performance. As a result, revenue from the clinical testing business increased 2.7% year on year.」

「In the clinical testing business, we strengthened coordination between our laboratories and headquarters, sought to develop the hospital and clinic markets, pursued solution-based sales to large facilities, conducted in-depth sales activities such as expanding sales of priority testing items to existing users, and implemented a laboratory utilization strategy using regional and separate laboratories to expand business performance. As a result, revenue from the clinical testing business increased 2.0% year on year.」

「In the clinical testing business, we strengthened coordination between our laboratories and headquarters, sought to develop the hospital and clinic markets, pursued solution-based sales to large facilities, conducted in-depth sales activities such as expanding sales of priority testing items to existing users, and implemented a laboratory utilization strategy using regional and separate laboratories to expand business performance. As a result, revenue from the clinical testing business increased 2.1% year on year.」

「In the clinical testing business, we strengthened coordination between our laboratories and headquarters, sought to develop the hospital and clinic markets, pursued solution-based sales to large facilities, conducted in-depth sales activities such as expanding sales of priority testing items to existing users, and implemented a laboratory utilization strategy using regional and separate laboratories to expand business performance. As a result, revenue from the clinical testing business increased 1.8% year on year.」

「In the clinical testing business, we continued to strengthen coordination between our laboratories and headquarters, sought to develop the clinic market, pursued solution-based sales to large facilities, conducted in-depth sales activities such as expanding sales of priority testing items to existing users, and advanced detailed profitability management for each business partner. Although business progressed at a pace exceeding plan in the first half, growth in patient and specimen numbers weakened from the third quarter onward partly due to adverse weather and other factors. As a result, revenue from the clinical testing business increased 2.2% from the previous fiscal year.」

「In the clinical testing business, we continued to strengthen coordination between our laboratories and headquarters, sought to develop the clinic market, pursued solution-based sales to large facilities using the FMS/branch laboratory model (leasing testing equipment and systems, providing operational guidance, and outsourcing the operation of in-house laboratories), conducted in-depth sales activities such as expanding sales of priority testing items to existing users, and advanced detailed profitability management for each business partner. As a result, revenue from the clinical testing business increased 3.0% year on year.」

「In the clinical testing business, we have strengthened coordination between our laboratories and headquarters, sought to develop the clinic market, pursued solution-based sales to large facilities using the FMS/branch laboratory model (leasing testing equipment and systems, providing operational guidance, and outsourcing the operation of in-house laboratories), conducted in-depth sales activities such as expanding sales of priority testing items to existing users, and advanced detailed profitability management for each business partner.」

「Through these initiatives, we will seek to further improve quality and productivity, enhance user services, and strengthen the competitiveness of the clinical testing business.」